Chappell Brandi J, Margot Nicolas A, Miller Michael D
Gilead Sciences, Inc., Foster City, California 94404, USA.
AIDS. 2007 Mar 30;21(6):761-3. doi: 10.1097/QAD.0b013e3280187533.
Patients with on-going HIV-1 replication and a K65R mutation in HIV-1 RT were assessed for further development of RT mutations while taking tenofovir disoproxil fumarate and other antiretroviral drugs. K65R was observed in 10 out of 536 treatment-experienced patients entering the study. K65R became undetectable in two patients, and the development of additional resistance mutations was minimal. Over 18 months, no patient developed multinucleoside resistance (Q151M or T69 insertions) and plasma viral loads were stable (median +0.04 log10 copies/ml).
对正在进行HIV-1复制且HIV-1逆转录酶存在K65R突变的患者，在服用替诺福韦酯富马酸盐及其他抗逆转录病毒药物期间，评估其逆转录酶突变的进一步发展情况。在进入该研究的536例有治疗史的患者中，有10例检测到K65R突变。两名患者体内的K65R突变变得无法检测到，且额外耐药突变的发生极少。在超过18个月的时间里，没有患者出现多核苷耐药（Q151M或T69插入），血浆病毒载量保持稳定（中位数为+0.04 log10拷贝/毫升）。
